» Articles » PMID: 35682554

SPARC Induces E-Cadherin Repression and Enhances Cell Migration Through Integrin αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jun 10
PMID 35682554
Authors
Affiliations
Soon will be listed here.
Abstract

Secreted protein acidic and rich in cysteine (SPARC), or osteonectin, is a matricellular protein that modulates interactions between cells and their microenvironment. SPARC is expressed during extracellular matrix remodeling and is abundant in bone marrow and high-grade prostate cancer (PCa). In PCa, SPARC induces changes associated with epithelial-mesenchymal transition (EMT), enhancing migration and invasion and increasing the expression of EMT transcriptional factor Zinc finger E-box-binding homeobox 1 (ZEB1), but not Zinc finger protein SNAI1 (Snail) or Zinc finger protein SNAI2 (Slug). It is unknown whether the SPARC-induced downregulation of E-cadherin in PCa cells depends on ZEB1. Several integrins are mediators of SPARC effects in cancer cells. Because integrin signaling can induce EMT programs, we hypothesize that SPARC induces E-cadherin repression through the activation of integrins and ZEB1. Through stable knockdown and the overexpression of SPARC in PCa cells, we demonstrate that SPARC downregulates E-cadherin and increases vimentin, ZEB1, and integrin β3 expression. Knocking down SPARC in PCa cells decreases the tyrosine-925 phosphorylation of FAK and impairs focal adhesion formation. Blocking integrin αvβ3 and silencing ZEB1 revert both the SPARC-induced downregulation of E-cadherin and cell migration enhancement. We conclude that SPARC induces E-cadherin repression and enhances PCa cell migration through the integrin αvβ3/ZEB1 signaling pathway.

Citing Articles

Spatial Transcriptomic Analysis of Surgical Resection Specimens of Primary Head and Neck Squamous Cell Carcinoma Treated with Afatinib in a Window-of-Opportunity Study (EORTC90111-24111).

Beyaert S, Loriot A, Machiels J, Schmitz S Int J Mol Sci. 2025; 26(5).

PMID: 40076457 PMC: 11898532. DOI: 10.3390/ijms26051830.


Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment.

Jiang H Cancer Manag Res. 2025; 17:219-237.

PMID: 39912095 PMC: 11796448. DOI: 10.2147/CMAR.S495169.


Emerin mislocalization during chromatin bridge resolution can drive prostate cancer cell invasiveness in a collagen-rich microenvironment.

Popeda M, Kowalski K, Wenta T, Beznoussenko G, Rychlowski M, Mironov A Exp Mol Med. 2024; 56(9):2016-2032.

PMID: 39218980 PMC: 11446916. DOI: 10.1038/s12276-024-01308-w.


Epithelial-mesenchymal plasticity (EMP) in wound healing: Exploring EMT mechanisms, regulatory network, and therapeutic opportunities.

Yao W, Wang Z, Ma H, Lin Y, Liu X, Li P Heliyon. 2024; 10(14):e34269.

PMID: 39108889 PMC: 11301171. DOI: 10.1016/j.heliyon.2024.e34269.


Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.

Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref A, Aljabali A Cell Mol Life Sci. 2024; 81(1):214.

PMID: 38733529 PMC: 11088560. DOI: 10.1007/s00018-024-05236-w.


References
1.
Galliher A, Schiemann W . Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2006; 8(4):R42. PMC: 1779461. DOI: 10.1186/bcr1524. View

2.
Shah P, Fong M, Kakar S . PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells. Oncogene. 2011; 31(26):3124-35. PMC: 3288952. DOI: 10.1038/onc.2011.488. View

3.
Nieto M, Cano A . The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol. 2012; 22(5-6):361-8. DOI: 10.1016/j.semcancer.2012.05.003. View

4.
Sartor O, de Bono J . Metastatic Prostate Cancer. N Engl J Med. 2018; 378(7):645-657. DOI: 10.1056/NEJMra1701695. View

5.
Chaffer C, San Juan B, Lim E, Weinberg R . EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016; 35(4):645-654. DOI: 10.1007/s10555-016-9648-7. View